Eradication of spurious adulterated and under standard quality drugs, a regulatory pertaining in Indian regulatory system
Keywords:
eradication spurious adulterated, standard quality drugs, regulatory pertaining, Indian regulatory systemAbstract
Drugs and pharmaceuticals have become an integral part of the lives of human beings as well as animals. They play an important role in saving lives, restoring health, preventing ailments, avoiding epidemics, and maintaining general well-being. In order to achieve this objective, they are required to be safe, efficacious, and of desired quality. As a deterrent and challenge in achieving this objective, the menace of Spurious, Adulterated, and Not of Standard Quality drugs have emerged as the biggest hurdles globally. Though Spurious and Adulterated drugs have attracted concerns of the society and Government agencies, the issue of Not of Standard Quality drugs has not been addressed satisfactorily. If a drug is not of desired quality, it shall not deliver the required benefits to the patient and thereby fails to achieve the basic objective of consuming the drug leading to dire consequences or even death.
Downloads
References
Available from: http://www.timesofindia.indiatimes.com/articles how/57318274.cms?utm_source=contentofinterest&utm_medium=text&utm_ campaign = cppst. [Last accessed on 2019 Sep 20].
Barnes K. New counterfeit report highlights worrying trends. Outsourcing Pharma 2007. Available from: http://www.outsourcingpharma. com/Contract-Manufacturing/New-counterfeit-report-highlights worrying- trends [Last cited on 2013 Apr 4].
Bate R, Tren R, Mooney L, Hess K, Mitra B, Debroy B, et al. Pilot study of essential drug quality in two major cities in India. PLoS One 2009;4:e6003.
Bate R, Zhe Jin G, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ 2011;30:1150-63.
Burke J. India rejects claims it exported fake medicine to Africa. The Guardian 2013. Available from: http://www.theguardian.com/world/2013/ Jan/02/India-rejects-fake-medicine Africa [Last cited on 2013 2nd February].
Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008;13:1062-72.
CDSCO. Report on a countrywide survey for spurious drugs. New Delhi: Ministry of Health and Family Welfare, Government of India; 2009 p. 3-4. Available from: http://www.cdsco.nic.in/report_book_13-7-10.pdf [Last accessed on 2013 Nov 20].
Current Scenario of Spurious and Substandard Medicines in India: A Systematic Review. Available from: https://www.researchgate. net/publication/273464064. [Last accessed on 2019 20th September].
Deccan Herald newspaper dated 25/08/2015, heading-“India needs stronger drug enforcement system."
Estevez, A. G., Espinosa, A. H. R., Rodríguez, D. L., & Leyva, T. F. (2019). Current approaches and controversies: legalization and non-legalization of drugs. International Journal of Health & Medical Sciences, 2(1), 26-32. https://doi.org/10.31295/ijhms.v2n1.85
Francis PA. National Programme to Counter Fake Drugs. Pharmabiz 2000. Available from: http://saffron.pharmabiz.com/article/detnews. asp?articleid=12328 and sectionid=47 [Last cited on 2013 Feb 12].
Furnham A, Valgeirsson H. The effect of life values and materialism on buying counterfeit products. J Socio Econ 2007;36:677-85.
Gentry JW, Putrevu S, Shultz C, Commuri S. How now Ralph Lauren? The separation of brand and product in a counterfeit culture. Lincoln, Nebraska; 2001. p. 258-65. Available from: http://www.acrwebsite.org/ search/view-conference-proceedings.aspx?Id=8485 [Last accessed on 2013 Nov 15].
Government of India, The Drugs and Cosmetics Act and Rules (Amendment) 2005. Ministry of Health and Family Welfare. Available from: http://www.cdsco.nic.in/forms/contentpage1.aspx?lid=1888 [Last cited on 2014 14th October].
Guidelines for taking action on samples of drugs declared spurious or not of standard quality in the light of enhanced penalties under The Drug and Cosmetic (Amendment) Act, 2008. New Delhi: CDSCO report; 2008 p. 1-13. Available from: http://www.cdsco.nic. in/writereaddata/Guidelines under new penal provisions9.pdf [Last accessed on 2013 Nov 13].
IMPACT. Counterfeit Medicines: an update on estimates. 2006. Available from: http://www.who.int/medicines/services/counterfeit/impact/TheNewEstimatesCounterfeit.pdf [Last accessed on 2013 Nov 18].
Jagadeesh K, Abhijith LM. Spurious Drugs: A Tragedy in Health System? Available from: http://www.rjms.in/index.php/rjms/ article/download/121001/83483. [Last accessed on 2019 20th September].
McLaughlin KE. Counterfeit medicine from Asia threatens lives in Africa. The Guardian 2012. Available from: http://www.theguardian. com/world/2012/dec/23/Africa-counterfeit-medicines-trade [Last cited on 2013 Feb 2].
Ministry of Health and Family Welfare. Report on Countrywide Survey for Spurious Drugs, Central Drugs Standard Control Organization. New Delhi: Ministry of Health and Family Welfare; 2009.
Morris J, Philip S. Counterfeit medicines in less developed countries. 2006. Available from: http://www.policynetwork.net/sites/default/files/ IPN_Counterfeits.pdf [Last accessed on 2013 Nov 18].
Mudur G. India to introduce the death penalty for peddling fake drugs. BMJ 2003;327:414.
Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012;12:488-96. Available from: http://www.ncbi.nlm.nih. gov/PubMed/22632187 [Last cited on 2014 May 24].
Newton PN, Amin A, Bird C, Passmore P, Dukes G, Tomson G, et al. The primacy of public health considerations in defining poor-quality medicines. PLoS Med 2011;8:e1001139.
Newton PN, Green MD, Fernandez FM, Day NP, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis 2006;6:602-13.
Newton PN, Green MD, Fernendez FM. Impact of poor-quality medicines in the “developing” world. Trends Pharmacol Sci 2010;31:99-101.
PIB. Generic Medicines. Press Information Bureau of India. 2012. Available from: http://www.pib.nic.in/newsite/erelease.aspx?relid=89323 [Last cited on 2013 8th January].
PIB. Infrastructure for seizure and testing of spurious drugs. India: Press Information Bureau of India; 2009. Available from: http://www. pib.nic.in/newsite/erelease.aspx?relid=55393 [Last cited on 2013 Jan 8].
PIB. Sale of Spurious Medicines in the Country. India: Press Information Bureau of India; 2010. Available from: http://www.pib.nic. in/newsite/erelease.aspx?relid=60987 [Last cited on 2013 Jan 9].
PIB. Survey on Spurious/Sub–Standard Drugs. India: Press Information Bureau of India; 2013. Available from: http://www.pib.nic.in/newsite/ release.aspx?relid=92384 [Last cited on 2013 Jan 8].
PIB. Suspension of Drugs. Press Information Bureau of India. 2010. Available from: http://www.pib.nic.in/newsite/erelease.aspx?relid=60818 [Last cited on 2013 8th January].
PSM. Counterfeit Drug Incident Encyclopedia. Partnership for Safe Medicines. 2013. Available from: http://www.safemedicines.org/ counterfeit-drug-incident-encyclopedia.html [Last cited on 2013 19th March].
PSM. Proposed methodology to conduct a study on the extent of spurious drugs in the supply chain of the Indian market. India: ???; 2010. Available from: http://www.safemedicinesindia.in/pdf/Methodology.pdf [Last accessed on ???].
Raufu A. India agrees to help Nigeria tackle the import of fake drugs. BMJ 2003;326:1234.
See M. Pharmaceutical quality: an urgent and unresolved issue. Lancet Infect Dis 2012;12:428-9.
Shepherd M. Vulnerable points in the US drug-distribution system. Manag Care 2004;13(Suppl 3):25-9.
Spuriousdrugs.Availablefrom:https://www.advocatekhoj.com/library/bareacts/drugsandcosmetics/17b.php?title=Drugs%20 and%20Cosmetics%20Act,%201940&STitle=Spurious%20 drugs. [Last accessed on 2019 Sep 20].
Substandard Drugs are a Bigger Problem for India than Fake. Available from: htps://www.economictimes.indiatimes. c o m / a r t i c l e s h o w / 6 9 1 3 7 9 8 3 . c m s ? f r o m = m d r & u t m _ source=contentofinterest&utm_medium=text&utm_ campaign=cppst. [Last accessed on 2019 Sep 20].
Taylor RB, Shakoor O, Behrens RH. Drug quality, a contributor to drug resistance? Lancet 1995;346:122.
The Spurious Drugs Gene and its Pervasiveness. Available from: https://www.ijme.in/articles/the-spurious-drugs-gene-and-its-pervasiveness/?galley=html. [Last accessed on 2019 20th September].
WHO. Medicines: Spurious/falsely-labeled/falsified/counterfeit (SFFC) medicines. Geneva: World Health Organization; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs275/en/index.html [Last cited on 2013 16th March].
WHO. The right to health. 2008. Available from: http://www.who.int/hhr/ activities/Right_to_Health_factsheet31.pdf [Last accessed on 2013 Nov 29].
WHO. The world medicines situation. World Health Organization. 2004. Available from: http://www.searo.who.int/LinkFiles/Reports_World_ Medicines_Situation.pdf [Last cited on 2010 Nov 30].
WHO. WHO medicines strategy: countries at the core, 2004–2007. World Health Organization. 2008. Available from: http://www.apps.who. int/medicinedocs/pdf/s5571e/s5571e.pdf [Last cited on 2010 Nov 30].
Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202
Wondemagegnehu E. Counterfeit and substandard drugs in Myanmar and Viet Nam. World Health Organization: Geneva; 1999. Available from: http://www.apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf [Last accessed on 2013 Nov 11].
World Bank. India. 2011. Available from: http://www.data.worldbank. org/country/India [Last cited on 2013 Mar 14].
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
